BACKGROUND: Literature data report an association between some vitamin D receptor (VDR) polymorphisms and different kinds of tumours, including malignant melanoma (MM). Only three VDR polymorphisms (FokI, TaqI and A-1012G) have been investigated in association with the presence of cutaneous MM or the development of metastases. OBJECTIVES: The present paper analyses for the first time the association between BsmI polymorphism and MM prevalence together with Breslow thickness. In addition, the FokI single nucleotide polymorphism was also determined. METHODS: One hundred and one patients with MM and 101 healthy donors matched for age and sex were enrolled. Molecular VDR typing was performed by means of restriction fragment length polymorphism analysis. RESULTS: All cases and controls were in Hardy-Weinberg equilibrium for BsmI, FokI and A-1012G. Significant associations were found between the BsmI bb genotype frequency and MM (P = 0.02) along with Breslow thickness (P = 0.001). This same behaviour was not observed for the FokI or A-1012G polymorphisms. Multivariate logistic regression analysis confirmed these significant results after correction for age, gender, skin type and MM localization. CONCLUSIONS: Although the biological meaning of the effects exerted by BsmI polymorphism is still under debate, the statistical association found in the present study suggests that further work should be done to verify this variant as a possible risk marker for MM and its aggressiveness, also considering that the real association may be due to other unknown genes linked to the BsmI b allele.
BACKGROUND: Literature data report an association between some vitamin D receptor (VDR) polymorphisms and different kinds of tumours, including malignant melanoma (MM). Only three VDR polymorphisms (FokI, TaqI and A-1012G) have been investigated in association with the presence of cutaneous MM or the development of metastases. OBJECTIVES: The present paper analyses for the first time the association between BsmI polymorphism and MM prevalence together with Breslow thickness. In addition, the FokI single nucleotide polymorphism was also determined. METHODS: One hundred and one patients with MM and 101 healthy donors matched for age and sex were enrolled. Molecular VDR typing was performed by means of restriction fragment length polymorphism analysis. RESULTS: All cases and controls were in Hardy-Weinberg equilibrium for BsmI, FokI and A-1012G. Significant associations were found between the BsmI bb genotype frequency and MM (P = 0.02) along with Breslow thickness (P = 0.001). This same behaviour was not observed for the FokI or A-1012G polymorphisms. Multivariate logistic regression analysis confirmed these significant results after correction for age, gender, skin type and MM localization. CONCLUSIONS: Although the biological meaning of the effects exerted by BsmI polymorphism is still under debate, the statistical association found in the present study suggests that further work should be done to verify this variant as a possible risk marker for MM and its aggressiveness, also considering that the real association may be due to other unknown genes linked to the BsmI b allele.
Authors: Rochelle Mandelcorn-Monson; Loraine Marrett; Anne Kricker; Bruce K Armstrong; Irene Orlow; Chris Goumas; Susan Paine; Stefano Rosso; Nancy Thomas; Robert C Millikan; Jason D Pole; Javier Cotignola; Cheryl Rosen; Peter A Kanetsky; Julia Lee-Taylor; Colin B Begg; Marianne Berwick Journal: Cancer Epidemiol Date: 2011-05-25 Impact factor: 2.984
Authors: Irene Orlow; Pampa Roy; Anne S Reiner; Sarah Yoo; Himali Patel; Susan Paine; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Nancy E Thomas; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Richard P Gallagher; Terence Dwyer; Peter A Kanetsky; Klaus Busam; Lynn From; Colin B Begg; Marianne Berwick Journal: Int J Cancer Date: 2011-04-25 Impact factor: 7.396
Authors: Juliette A Randerson-Moor; John C Taylor; Faye Elliott; Yu-Mei Chang; Samantha Beswick; Kairen Kukalizch; Paul Affleck; Susan Leake; Sue Haynes; Birute Karpavicius; Jerry Marsden; Edwina Gerry; Linda Bale; Chandra Bertram; Helen Field; Julian H Barth; Isabel Dos Santos Silva; Anthony Swerdlow; Peter A Kanetsky; Jennifer H Barrett; D Timothy Bishop; Julia A Newton Bishop Journal: Eur J Cancer Date: 2009-07-15 Impact factor: 9.162
Authors: Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey Journal: Anticancer Agents Med Chem Date: 2014-01 Impact factor: 2.505
Authors: Shenying Fang; Amaury Vaysse; Myriam Brossard; Yuling Wang; Defeng Deng; Quan Liu; Peter Zhang; Kejing Xu; Ming Li; Runhua Feng; Huey Liu; Yifang Dang; Wei Chen; Victor Prieto; Jeffrey E Gershenwald; Merrick I Ross; Brenna Matejka; Jared Malke; Lauren E Haydu; John D Reveille; Dawen Sui; Roland L Bassett; Nadya Koshkina; Marie Françoise Avril; Mason Lu; Qingyi Wei; Florence Demenais; Christopher I Amos; Jeffrey E Lee Journal: J Invest Dermatol Date: 2016-08-06 Impact factor: 8.551